Quest PharmaTech (CVE:QPT) Trading Down 25% – What’s Next?

Shares of Quest PharmaTech Inc. (CVE:QPT) fell 25% on Thursday . The company traded as low as C$0.03 and last traded at C$0.03. 123,238 shares traded hands during mid-day trading, an increase of 414% from the average session volume of 23,982 shares. The stock had previously closed at C$0.04.

Quest PharmaTech Price Performance

The company has a market cap of C$5.07 million, a P/E ratio of -30.00 and a beta of 0.00. The firm’s 50-day moving average is C$0.04 and its two-hundred day moving average is C$0.04. The company has a debt-to-equity ratio of 4.35, a current ratio of 0.40 and a quick ratio of 0.52.

About Quest PharmaTech

Quest PharmaTech Inc, a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class.